Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $422M | $436M | $705M | $861M | $926M | $1.14B | $1.46B | $1.89B | $2.11B | $2.53B |
| Revenue growth | — | 3.5% | 61.5% | 22.2% | 7.5% | 23.4% | 27.8% | 29.2% | 11.8% | 20.0% |
| Operating income | $52.5M | $64.9M | $101M | $127M | $167M | $199M | $279M | $337M | $447M | $535M |
| Operating margin | 12.5% | 14.9% | 14.3% | 14.8% | 18.0% | 17.4% | 19.1% | 17.9% | 21.2% | 21.1% |
| Net income | $13.4M | $39.1M | $73.2M | $100M | $145M | $182M | $245M | $283M | $404M | $451M |
| Net margin | 3.2% | 9.0% | 10.4% | 11.7% | 15.7% | 15.9% | 16.8% | 15.0% | 19.2% | 17.8% |
| EPS (diluted) | $0.37 | $0.98 | $1.97 | $2.67 | $3.84 | $4.81 | $7.28 | $8.88 | $12.63 | $15.28 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $91.7M | $97.4M | $157M | $202M | $259M | $263M | $388M | $433M | $609M | $713M |
| Capital expenditures | $13.5M | $11.7M | $16.0M | $17.9M | $31.3M | $28.3M | $36.9M | $36.6M | $36.5M | $31.4M |
| Free cash flow | $78.2M | $85.7M | $141M | $184M | $227M | $235M | $351M | $397M | $572M | $682M |
| Share buybacks | $0.00 | $156M | $0.00 | $0.00 | $98.3M | $62.1M | $848M | $144M | $170M | $917M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $37.1M | $26.5M | $23.3M | $132M | $278M | $461M | $28.3M | $245M | $669M | $497M |
| Total assets | $979M | $951M | $968M | $1.00B | $1.39B | $1.66B | $1.35B | $1.66B | $2.10B | $1.98B |
| Total liabilities | $368M | $447M | $378M | $406M | $585M | $707M | $966M | $1.10B | $1.28B | $1.52B |
| Long-term debt | $151M | $205M | $79.7M | $0.00 | — | — | — | — | — | — |
| Shareholders' equity | $611M | $509M | $599M | $726M | $806M | $953M | $386M | $559M | $826M | $459M |
| Retained earnings | -$9.58M | -$120M | -$41.5M | -$32.3M | $115M | $235M | -$360M | -$222M | $8.17M | -$460M |
| Shares (wtd avg diluted) | 36.3M | 39.8M | 36.9M | 37.6M | 37.7M | 37.7M | 33.7M | 31.8M | 32.0M | 29.5M |
Every figure is extracted from Medpace Holdings, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.